Arşiv logosu
  • Türkçe
  • English
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
Arşiv logosu
  • Koleksiyonlar
  • Sistem İçeriği
  • Araştırmacılar
  • Projeler
  • Birimler
  • Analiz
  • Türkçe
  • English
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
  1. Ana Sayfa
  2. Yazara Göre Listele

Yazar "Bozkurt, S." seçeneğine göre listele

Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
  • Küçük Resim Yok
    Yayın
    HE4: really a novel biomarker for ovarian cancer?
    (I R O G CANADA, INC, 2017) Yucel, E.; Ilter, E.; Aksungar, F. B.; Celik, A.; Peker, B. H.; Serifsoy, E.; Bozkurt, S.
    Ovarian cancer forms 4% of all cancers and approximately 23% of all gynecological cancers in women and is responsible for the 47% of deaths related to cancers of the genital tract of women. Tumor markers are the biochemical substances which can be detected in the presence of tumors. Generally they are either the products of tumoral tissues or secreted from the normal cells which are in the interaction with tumoral ones. The present authors attempted to determine the efficacy of the tumor marker CA-125 and HE4 to differentiate the malign cases from the benign adnexal masses. A total of 76 patients with the appropriate criteria were included in the study. They were divided into three groups; healthy control group (n=31), ones with benign masses (n=23), and ones with malign ovarian masses (n=22). In the study, when the cut-off values were accepted as 55I U/ml for CA-125 and 150 pM for HE4 in differentiation of benign and malign groups, the sensitivity was found as 59.09%, specificity 91.3%, PPV 86.67% and NPV 70% LR = +6.8. This combination gives one false positive result to every five positive cases which were detected as high. With the combination of CA-125 and HE4, the value of sensitivity was found decreased as expected, although the value of the specificity increased.
  • Küçük Resim Yok
    Yayın
    INSULAR TYPE OVARIAN CARCINOID TUMOR ARISING IN A MATURE CYSTIC TERATOMA
    (LIPPINCOTT WILLIAMS & WILKINS, 2015) Gursoy, A.; Ilter, E.; Yener, N.; Celik, A.; Peker, B. H.; Bozkurt, S.; Ozekici, U.; Apa, D. D.
    …
  • Küçük Resim Yok
    Yayın
    Overactive Bladder Syndrome in Women
    (Springer International Publishing, 2022) Peker, B.H.; Gürsoy, A.; İlter, E.; Çelik, A.; Yucel, E.; Bozkurt, S.; Özekici, U.
    Functional electrical stimulation (FES) is one of the first options for conservative treatment in overactive bladder syndrome (OAB). The role of FES in patients whom not exactly satisfied with anticholinergic treatment is unclear. In this study, pre- and post-treatment assessment of women whom not satisfied with anticholinergics was compared. Adding FES treatment to patients whom not full satisfied with anticholinergic treatment can increase cure rates of OAB cases. © MIPS MediterraneanIncontinence Pelvic Floor Society 2022.
  • Küçük Resim Yok
    Yayın
    Single-Incision Slings
    (Springer International Publishing, 2022) Peker, B.H.; Gürsoy, A.; İlter, E.; Çelik, A.; Yucel, E.; Bozkurt, S.; Özekici, U.
    Recently, single-incision slings (SIMs) are introduced for surgical treatment of stress urinary incontinence. In this study, the long-term results and complications of transobturator tension-free vaginal tape (TVT-O, Gynecare) and a single-incision tape procedure (Contasure-Needleless, Neomedic Int.) were compared. Both procedures are found to have similar outcomes except that single-incision slings had lower rate of de novo urgency. © MIPS MediterraneanIncontinence Pelvic Floor Society 2022.

| Maltepe Üniversitesi | Kütüphane | Açık Bilim Politikası | Açık Erişim Politikası | Rehber | OAI-PMH |

Bu site Creative Commons Alıntı-Gayri Ticari-Türetilemez 4.0 Uluslararası Lisansı ile korunmaktadır.


Maltepe Üniversitesi Kütüphane ve Dokümantasyon Daire Başkanlığı, İstanbul, TÜRKİYE
İçerikte herhangi bir hata görürseniz lütfen bize bildirin

DSpace 7.6.1, Powered by İdeal DSpace

DSpace yazılımı telif hakkı © 2002-2025 LYRASIS

  • Çerez Ayarları
  • Gizlilik Politikası
  • Son Kullanıcı Sözleşmesi
  • Geri Bildirim